AI Triage in Mammography Moves From Hype to Workforce Strategy
Fresh discussion around AI triage in mammography centers on a practical question: can screening programs reduce radiologist workload without sacrificing safety? That framing reflects a broader market shift from AI as an accuracy upgrade to AI as an operational response to screening capacity pressure.
Mammography AI is no longer just being judged on whether it can find more cancers in reader studies. The sharper question now is whether it can safely remove work from screening workflows. That matters because breast screening programs in many regions face rising volumes, reader shortages, and growing pressure to maintain turnaround times without inflating costs.
Triage models are appealing because they can theoretically identify clearly low-risk exams for lighter review pathways while escalating suspicious cases. In principle, that could preserve human attention for the studies that need it most. But the downside risk is obvious: even small misses in a population screening context can become politically and clinically unacceptable.
The strategic issue is therefore one of trust architecture, not just algorithm design. Programs need to know where AI can sit in the workflow, how false negatives are monitored, and what degree of human oversight remains mandatory. That makes implementation evidence, governance, and auditing just as important as headline sensitivity figures.
If mammography triage proves robust, it could become one of the clearest examples of AI delivering labor productivity in a highly standardized clinical domain. That would have implications beyond breast imaging, offering a template for how AI gets deployed in screening: not as a replacement radiologist, but as a system-level workload manager with carefully bounded autonomy.